Results 51 to 60 of about 165,965 (304)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD [PDF]

Frontiers in Endocrinology, 2018
Along the obesity pandemic, the prevalence of non-alcoholic fatty liver disease (NAFLD), often regarded as the hepatic manifestation of the metabolic syndrome, increases worldwide representing now the prevalent liver disease in western countries. No pharmacotherapy is approved for the treatment of NAFLD and, currently, the cornerstone treatment is ...
Marta Seghieri, Marta Seghieri, Alexander S. Christensen, Andreas Andersen, Anna Solini, Filip K. Knop, Filip K. Knop, Filip K. Knop, Tina Vilsbøll, Tina Vilsbøll   +9 more
openaire   +6 more sources

Glucagon-like peptide-1 receptor agonists for treatment of diabetes and obesity: advantage of oral delivery

Frontiers in Drug Delivery
GLP-1 receptor agonists ((GLP-1 RAs) are currently receiving a lot of attention because of their impact in diabetes, weight loss and other areas. While GLP-1 RAs in injectable form are highly efficacious, further work is required to develop oral versions
R. R. C. New, R. R. C. New, M. Bogus, G. N. Travers, U. Hahn, A. Vaiceliunaite, M. Burnet, J. H. Wang, H. Wen   +8 more
doaj   +1 more source

A Comprehensive Review on the Pharmacokinetics and Drug−Drug Interactions of Approved GLP-1 Receptor Agonists and a Dual GLP-1/GIP Receptor Agonist

Drug Design, Development and Therapy
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are peptide-derived analogs that were initially investigated to treat type 2 diabetes. Recently, a drug targeting the receptors of both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP ...
Jee Sun Min, Seongjun Jo, Sangyoung Lee, Duk Yeon Kim, Da Hyun Kim, Chae Bin Lee, Soo Kyung Bae   +6 more
semanticscholar   +1 more source

GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs

Cardiovascular Diabetology, 2021
Background A meta-analysis is presented of cardiovascular outcome trials (CVOTs) comparing glucagon-like peptide-1 receptor agonists (GLP-1RA) versus placebo on cardiorenal outcomes in patients with type 2 diabetes mellitus (T2DM).
D. Giugliano, L. Scappaticcio, M. Longo, P. Caruso, M. Maiorino, G. Bellastella, A. Ceriello, P. Chiodini, K. Esposito   +8 more
semanticscholar   +1 more source

Postoperative Aspiration Pneumonia Among Adults Using GLP-1 Receptor Agonists

JAMA Network Open
This cohort study investigates whether use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with postoperative aspiration pneumonia among patients undergoing common surgical procedures.
Yuan-Hsin Chen, Thomas Zink, Ya-Wen Chen, Darren Z. Nin, C. Talmo, Brian L. Hollenbeck, Andrew R. Grant, Ruijia Niu, David C. Chang, Eric L. Smith   +9 more
semanticscholar   +1 more source

The comparative efficacy of SGLT-2 inhibitors and GLP-1 receptor agonists on metabolic benefits in T2DM patients: a systematic review and network meta-analysis

European Journal of Medical Research
Background SGLT-2 inhibitors and GLP-1 receptor agonists exhibit metabolic benefits on improving obesity, diabetes, hypertension and hyperlipidemia, but the differences between them remain unclear.
Jingkai Tong, Nana Li, Fang Hu, Yingying Yue   +3 more
doaj   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonist Use in Obese Patients Is Associated With Decreased Risk of Revision and Retears After Arthroscopic Rotator Cuff Repair

Arthroscopy, EarlyView.
Purpose To evaluate the impact of preoperative glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) use on medical complications, emergency department use, and orthopaedic complications in obese patients undergoing arthroscopic rotator cuff repair. Methods Obese patients (defined by relevant ICD‐10 codes and confirmed by body mass index measurements ...
Argen Omurzakov, Arsen M. Omurzakov, Robert J. Burkhart, James E. Voos, Jacob G. Calcei, John M. Apostolakos   +5 more
wiley   +1 more source

Efficacy of GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists in managing MALFD: a meta-analysis of randomized controlled trials

BMC Gastroenterology
Background Metabolic dysfunction-associated fatty liver disease (MAFLD) affects up to 30% of the global population, yet effective pharmacological treatments remain limited. This systematic review and meta-analysis evaluated the efficacy of GLP-1 receptor
Surtika Tamilwanan, Zoriah Aziz, Lim Yan Rong, Ahmad Naoras Bitar, Raghdaa Hamdan Al Zarzour, Salah A. Alshehade   +5 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists in Chronic Kidney Disease: Mechanisms and Clinical Perspectives

Kidney Medicine
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin-based therapies initially developed for the management of type 2 diabetes. In addition to improving glycemic control and promoting weight loss, these agents have demonstrated cardiovascular ...
Mackenzi Meier, Jamessa Cummings, Mohammed Abdelsaid, Jose Feliciano, Jazmin Eusebe, Hanna Stirn, Maha Coucha   +6 more
doaj   +1 more source

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application

Diabetes & Metabolism Journal
Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease and significantly increases cardiovascular risk and mortality. Despite conventional therapies, including renin-angiotensin-aldosterone system inhibitors, substantial residual ...
J. Bae
semanticscholar   +1 more source